The company is launching the test in Europe. Bruker said the kit includes all necessary reagents to produce up to 96 results in under two hours.

Omar Ford

July 27, 2020

1 Min Read

Bruker is launching a second-generation assay in Europe for the detection of the SARS-CoV-2 virus, which causes the respiratory and systemic disease COVID-19.

The Billerica, MA-based company said the FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay has been validated for respiratory samples (nasopharyngeal swabs and oropharyngeal swabs in viral transport medium) using commonly available laboratory real-time PCR thermocyclers.

The kit includes all necessary reagents to produce up to 96 results in under two hours. It is validated for use on Bruker´s GenoXtract (GXT) automated nucleic acid extraction devices with associated extraction kits.

“With the FluoroType SARS-CoV-2 plus assay we expand our portfolio by an assay with added value by detecting two gene targets,” Dr. Wolfgang Pusch, Executive VP Microbiology & Diagnostics at Bruker Daltonics said in a release. “Additionally, the differentiation from other human coronaviruses, which for example can cause a common cold, reduces the risk of false-positive results due to potential cross-reactivity. We expect that these analytical features enable a very robust second-generation PCR assay with the highest sensitivity and specificity.”

Bruker said in a pilot phase and in collaboration with several partners, it has recently also begun to offer CE-IVD marked serology antibody tests to detect previous COVID-19 infection in selected European countries, as well as a CE-IVD point-of-care (POC) antigen tests to screen for active CV19 infections in under two hours.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like